I'm LongbridgeAI, I can summarize articles.BROTHER's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical, recently received approval from the National Medical Products Administration for the marketing of Iohexol Injection. This product is primarily used for various imaging examinations, featuring low viscosity and good safety. This approval will provide qualification assurance for BROTHER Pharmaceutical's commercial sales, enrich the company's iodine contrast agent product line, and enhance market competitiveness
According to the Zhitong Finance APP, BROTHER Technology (002562.SZ) announced that its wholly-owned subsidiary Zhejiang Brother Pharmaceutical Co., Ltd. (referred to as "Brother Pharmaceutical") recently received the Drug Registration Certificate for Iohexol Injection issued by the National Medical Products Administration. Iohexol Injection is mainly used for cardiovascular angiography, peripheral artery angiography, venography, coronary angiography, cerebrovascular angiography, urinary tract angiography, lumbar/thoracic and cervical spinal angiography, joint angiography, and CT enhancement examinations, characterized by low viscosity and good safety.
The approval of Iohexol Injection for market launch marks that this product can officially be sold in China, providing qualification assurance for Brother Pharmaceutical's commercial sales of this product, while further enriching the company's iodinated contrast agent product line and enhancing the company's market competitiveness in the field of contrast agents